Impact of smoking on life expectancy in HIV infection
By Gareth Hardy, HIV i-Base Smoking may double the risk of mortality for HIV positive people according to results from a large collaborative HIV cohort study of people who have been on ART for more...
View ArticleCMV associated with 50% increased risk of non-AIDS related mortality in HIV...
Gareth Hardy, HIV i-Base Coinfection with cytomegalovirus (CMV) infection may be associated with a 50% higher risk of non-AIDS defining mortality compared to HIV people who are CMV negative, according...
View ArticleNeurocognitive disorder, persistent inverted CD4:CD8 ratios and immune...
Gareth Hardy, HIV i-Base Given the concerns that HIV positive people commonly have about neurocognitive changes, a recent paper published in the Annals of Clinical and Translational Neurology is...
View ArticleDoubled hypogonadism rate in middle-aged men with HIV: fat is a factor
Mark Mascolini, for NATAP.org Hypogonadism (low testosterone) affected 12% of middle-aged HIV-positive men, a rate twice that seen in the general population, according to results of a preliminary study...
View ArticleImmediate ART in START linked to greater bone loss over three years
Mark Mascolini, natap.org People randomised to begin antiretroviral therapy (ART) immediately in the international START trial had steeper declines in bone mineral density (BMD) than people randomised...
View ArticleNo difference in neuropsychological test results between early and delayed...
Mark Mascolini, natap.org Through 3.3 years of follow-up, people randomised to immediate antiretroviral therapy (ART) in the international START trial had neuropsychological (NP) test results similar...
View ArticleRenal monitoring in HIV positive patients: a new review
Simon Collins, HIV i-Base A useful and comprehensive review of evidence for frequency of renal monitoring, including which tests to use has been published by Jean Cyr Yombi and colleagues in the...
View ArticleAlcohol risks are higher in HIV positive people and linked to increased...
Gareth Hardy, HIV i-Base Alcohol may affect HIV positive people differently and be an independent factor related to all cause mortality, according to a paper from one of the largest US cohort studies....
View ArticlePersistent HPV infection may be related to tissue type in HIV positive people
Gareth Hardy, i-Base Rhonda Meys and colleagues at Chelsea and Westminster Hospital have conducted the first study to examine the relationship between persistent warts, HPV infection and tissue type in...
View ArticleEfavirenz associated with suicide risk in analysis from START study
Simon Collins, HIV i-Base Suicide-related side effects are an important concern with efavirenz. Given how widely efavirenz continues to be used the main safety concern is whether current prescribing...
View ArticleFanconi-like lab abnormalities reported with daily PrEP: importance of...
Simon Collins, HIV i-Base The first case of Fanconi syndrome associated with PrEP was reported in a poster at the 18th International Workshop on Comorbidities and Adverse Drug Reactions in HIV. [1]...
View ArticleNeurological side effects with integrase inhibitors cause discontinuations in...
Simon Collins, HIV i-Base An analysis from use of integrase inhibitors in clinical practice reported significantly higher rates of discontinuations related to side effects than seen in clinical studies...
View ArticleRaltegravir increases waist circumference compared to boosted PIs: greater...
Simon Collins, HIV i-Base A large US ACTG study reported significantly different body changes with raltegravir compared to combinations using a boosted PI. [1] While the results presented at the 18th...
View ArticleBone loss and recovery in MSM aged 13-24 using PrEP for a year
Simon Collins, HIV i-Base Results from an open-label study in young people using PrEP showed that impact on bone health might be important is daily dosing is used for many years. [1] In the short-term,...
View ArticleFurther reports of CNS-related side effects with dolutegravir
Simon Collins, HIV i-Base Several studies at Glasgow 2016 provided additional information about real world experience with the integrase inhibitor dolutegravir. Although registrational studies showed...
View ArticleCase report of capsulitis with elvitegravir and cobicistat (EVG/c)
Roy Trevelion, HIV i-Base Although capsulitis was associated with early protease inhibitors (predominantly indinavir) a recent case report now links this to the integrase inhibitor elvitegravir/c...
View ArticleHigh rates of of undocumented efavirenz-related side effects in Uganda
Simon Collins, HIV i-Base Although CNS side effects associated with efavirenz have led to newer drugs being recommended in in high income countries, WHO guidelines for low and middle income countries...
View ArticleUnexpected side effects with generic abacavir – and potential for rare...
Potential side effects with generic abacavir
View ArticleIncreased frequency and progression of kidney disease in HIV positive people
Gareth Hardy, HIV i-Base A recent review in JID reported higher rates of renal complications in HIV positive people that was not explained by traditional risk factors. Chronic kidney disease (CKD) is...
View ArticleEffects of the anti-inflammatory antibody canakinumab on heart disease and...
Richard Jefferys, TAG Inflammation is increasingly recognised as an immunological double-edged sword: it contributes importantly to the response to infection, but can also cause serious collateral...
View ArticleDolutegravir linked to less sleep but not cardiovascular or other CNS side...
Polly Clayden, HIV i-Base Meta-analysis of randomised trials presented at EACS 2017 found higher risk of insomnia for dolutegravir (DTG) compared with other antiretrovirals (ARVs). But no difference...
View ArticleMeta-analysis reports no significant risk of cardiac, IRIS or suicide with...
Polly Clayden, HIV i-Base Meta-analysis shows no significant effect of dolutegravir on the risk of cardiac, IRIS or suicide-related serious adverse events. There was a higher risk of insomnia with...
View ArticleRate of bone loss on ART slows after the first year
Simon Collins, HIV i-Base A sub-study from the international START study provided reassuring data that the initial loss in bone mineral density (BMD) during the first year of ART, slowed during...
View ArticleReducing risk of myocardial infarction (MI) in HIV positive people
Satyajit Das, HIV i-Base Platelets, leucocytes and thrombosis Several research groups have tried to explain the potential mechanism for the association of increased MI risk and abacavir use reported by...
View ArticleBHIVA statement on potential safety signal in infants born to women...
The BHIVA pregnancy guidelines writing group have issued recommendations on DTG use for pregnant women and those of childbearing age. BHIVA statement on potential safety signal in infants born to women...
View ArticleBoosted darunavir is associated with higher cardiovascular risk in D:A:D...
Simon Collins, HIV i-Base Compared to HIV positive people using other HIV drugs, cumulative use of the boosted protease inhibitor darunavir/ritonavir was associated with an approximately 60% higher...
View ArticleEfavirenz side effects and other drug-drug interactions are common in Ugandan...
Polly Clayden, HIV i-Base Drug-drug interactions and side effects, associated with currently-used first-line ART, are under-reported and managed in Uganda, according to findings presented at the 19th...
View ArticleCannabis-based products for medicinal use: Guidance to clinicians
Simon Collins, HIV i-Base Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the...
View ArticleFrailty in older HIV positive people: independent associations with serious...
Simon Collins, HIV i-Base Frailty is a critical age-related risk that over the last ten years has increasingly been highlighted as an important factor in older people living with HIV. [1, 2, 3] A new...
View ArticleAre integrase inhibitors linked to weight gain? – an evidence review
Polly Clayden, HIV i-Base HIV treatment with integrase inhibitors appears to lead to greater increases in body weight than with other antiretrovirals. The effect seems to be more pronounced for women...
View ArticleINSTI and weight gain: reports from CROI 2019
Polly Clayden, HIV i-Base Several presentations at CROI 2019 showed data from analyses of INSTI-associated weight gain from mostly US cohorts (and one prevention study). Although topical and a...
View ArticleAdopting new US blood pressure targets for HIV positive people could reduce...
Simon Collins, HIV i-Base A review of management of HIV positive people with high blood pressure (BP) in a large London hospital showed 42% were not well controlled but care was improved after move to...
View ArticleType 2 diabetes is often undermanaged in HIV positive people
Simon Collins, HIV i-Base A retrospective review of patient notes (up to December 2015) from a large London HIV clinic reported prevalence of type 2 diabetes mellitus (T2DM) of 3% (256/9131 patients)...
View ArticleDolutegravir-based first-line non-inferior to efavirenz-based ART but...
Polly Clayden, HIV i-Base Dolutegravir (DTG)-based ART was non-inferior to efavirenz (EFV)-based treatment in a South African study comparing three first-line regimens. [1, 2] Participants receiving...
View ArticleGreater weight gain with INSTI-based than non-INSTI-based ART among women in...
Polly Clayden, HIV i-Base Switch to an integrase strand transfer inhibitor (INSTI) was associated with significant increases in body weight, body circumferences, and fat percentages compared to...
View ArticlePossible higher diabetes risk with raltegravir or PIs than NNRTIs
Mark Mascolini, natap.org Starting antiretroviral therapy (ART) with an integrase inhibitor (INSTI) or protease inhibitor (PI) may confer a higher risk of diabetes than starting with a nonnucleoside...
View ArticleSwitching from TDF to TAF linked to higher BMI and cardio risk
Mark Mascolini, natap.org A 110-person retrospective study found increasing body mass index (BMI) and atherosclerotic cardiovascular disease (ASCVD) risk after a switch from tenofovir disoproxil...
View ArticleWeight gain and metabolic syndrome with dolutegravir and TAF: results from...
Polly Clayden, HIV i-Base Dolutegravir (DTG) in combination with tenofovir alafenamide (TAF) is linked to increases in weight and clinical obesity – according to data from the ADVANCE trial presented...
View ArticleWeight changes with doravirine-based first line therapy
Simon Collins, HIV i-Base Given the concerns about weight gain with integrase inhibitors and NRTIs, especially dolutegravir and TAF, changes in weight and BMI should now be reported for other recently...
View ArticlePostpartum weight gain is higher with dolutegravir- compared with...
Polly Clayden, HIV i-Base Two analyses presented at CROI 2020 show higher weight postpartum among African women receiving dolutegravir (DTG) compared with efavirenz (EFV). [1, 2] Concerns are growing...
View ArticlePredicted diabetes risk with first-line ART regimens: results from the...
Polly Clayden, HIV i-Base Increased risk of diabetes predicted for people receiving tenofovir alafenamide (TAF), emtricitabine (FTC) and dolutegravir (DTG) in the ADVANCE trial – according to an...
View ArticleDolutegravir associated with hyperglycaemia in people switching first-line...
Polly Clayden, HIV i-Base Hyperglycaemia was reported in Uganda among people switching first-line regimens to dolutegravir-based ART, in a letter to Lancet HIV, published online 24 February 2020. The...
View ArticlePredicted diabetes risk with first-line ART regimens: results from the...
Polly Clayden, HIV i-Base Increased risk of diabetes predicted for people receiving tenofovir alafenamide (TAF), emtricitabine (FTC) and dolutegravir (DTG) in the ADVANCE trial – according to an...
View ArticleObesity linked to dolutegravir, especially with TAF, could increase risk of...
Polly Clayden, HIV i-Base Treatment-emergent obesity with tenofovir alafenamide (TAF)/ emtricitabine(FTC)/dolutegravir (DTG) and to a lesser extent, tenofovir disoproxil fumarate (TDF)/FTC/DTG, could...
View ArticleDolutegravir associated with weight gain in African ART programmes: findings...
Polly Clayden, HIV i-Base People with HIV receiving TLD (tenofovir disoproxil fumarate/lamivudine/dolutegravir) in sites across four African countries had increased rates of developing high BMI...
View ArticleWeight gain with integrase inhibitors and TAF: three reports from AIDS 2020
Polly Clayden, HIV i-Base More presentations at AIDS 2020 showed weight gain among people with HIV treated with integrase strand inhibitors (INSTI) and tenofovir alafenamide (TAF). We previously...
View ArticleWeight gain with dolutegravir-based ART in Nigerian cohort
Polly Clayden, HIV i-Base Observational data from Nigeria, presented at HIV Glasgow 2020, showed weight gain in people with HIV switching to dolutegravir (DTG)-based ART. This appeared to plateau by 24...
View ArticleChronic kidney disease (CKD) in HIV positive people linked to time with low...
Simon Collins, HIV i-Base The large prospective D:A:D cohort, with approximately 49,000 participants, looked at a range of markers of HIV-related immunosuppression, including baseline, nadir and...
View ArticleNICE guidelines on management of chronic pain: exercise but not opiods
Simon Collins, HIV i-Base On 7 April 2021, the National Institute for Clinical Excellence (NICE) issued long-awaited guidelines for the management of chronic pain in adults aged 16 and older. The...
View ArticleWeight changes on ART and how to lose weight successfully
Simon Collins, HIV i-Base Several presentations at the BHIVA/BASHH conference looked at the controversial issue of weight gain. The opening lecture from Dr Anton Pozniak from the Chelsea and...
View Article
